Praxis Precision Medicines ( (PRAX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Praxis Precision Medicines shares are climbing as traders look ahead to pivotal Phase 3 data for its essential tremor drug candidate, ulixacaltamide, set to be showcased at the American Academy of Neurology meeting starting tomorrow. Sentiment has also improved after a week of strong regulatory news, including FDA acceptance of the New Drug Application for ulixacaltamide and Priority Review for its epilepsy therapy, relutrigine.
Adding to the momentum, Wall Street analysts have recently launched upbeat coverage with bullish ratings that highlight growing faith in Praxis’s late‑stage neuroscience portfolio. These new opinions come with higher price targets, signaling expectations for further upside if the company can successfully convert its clinical and regulatory advances into commercial success.
More about Praxis Precision Medicines
YTD Price Performance: 15.33%
Average Trading Volume: 449,897
Technical Sentiment Signal: Buy
Current Market Cap: $9.47B
For further insights into PRAX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.